Injective (INJ) is showing renewed bullish momentum as analysts highlight a potential breakout toward higher price targets after reclaiming key support. At the same time, its SEC transfer agent filing marks a significant step toward regulated on-chain securities, strengthening its long-term role in the real-world asset (RWA) ecosystem despite short-term market weakness.
